A sprayable hydrogel loaded with fusion cellular vesicles (Fus-CVs) achieves dual functionality in immune checkpoint blockade and lipid metabolic regulation but also offers localized controlled release, and reduced systemic toxicity, thereby presenting a clinically translatable strategy for postoperative recurrence prevention.
Abstract
Surgical resection often leaves residual lesions that lead to tumor recurrence and high mortality across various cancer types, a challenge that is particularly pronounced in oral squamous cell carcinoma. Herein, we developed a sprayable hydrogel loaded with fusion cellular vesicles (Fus-CVs) and characterized its structural and mechanical properties for the prevention of postoperative tumor recurrence. Fus-CVs co‑express PD‑1 to engage PD‑L1 on tumor cells and CD36 to competitively bind oxidized lipids in the tumor microenvironment, thereby effectively reversing T cell exhaustion and restoring T cell effector function. Additionally, the sprayable hydrogel, formed by crosslinking sodium alginate (SA) with the ionic solution (calcium chloride, CaCl2; manganese chloride, MnCl2), enables sustained local delivery of Fus‑CVs to potentiate T cell‑mediated killing of residual tumor cells. In vitro experiments and primary tumor model confirmed that Fus‑CVs specifically achieve dual targeting of PD-L1 on tumor cells and oxidized lipids in the tumor microenvironment, reverse T cell exhaustion and achieve combination therapy. In an established postoperative recurrence mouse model, the SA solution containing Fus-CVs and the ionic solution could be co-sprayed to rapidly form a conformal, uniform and stable layer on irregular tissue surfaces, enabling sustained local release of Fus-CVs and achieve effective tumor recurrence suppression. Fus‑CVs-loaded sprayable hydrogel not only achieves dual functionality in immune checkpoint blockade and lipid metabolic regulation but also offers localized controlled release, and reduced systemic toxicity, thereby presenting a clinically translatable strategy for postoperative recurrence prevention.
Breast cancer relapse and therapeutic resistance recurrence are mainly due to the presence of breast cancer-associated cancer stem cells (bCSCs), which are inadequately eradicated by conventional chemotherapeutic agents. To mitigate these challenges, we engineered an injectable in situ-forming gelatin hydrogel capable...
To address the clinical need for localized therapy for pancreatic cancer, an injectable, self-healing nanocomposite hydrogel (GPPA-Mn@DOX) was rationally designed and developed. The hydrogel consists of phenylboronic acid-modified gelatin (Gel-PBA) and polyvinyl alcohol (PVA), which are crosslinked through dynamic boro...
Chuan-Cang Xie, Yan-Yan Feng, Li-Ping Zhu et al.· Biochemical and Biophysical...· 0 citations
Breast cancer remains one of the leading causes of cancer-related mortality in women worldwide, and sonodynamic therapy (SDT) has emerged as a promising non-invasive antitumor therapeutic modality. In this work, an injectable alginate (ALG) hydrogel loaded with an iridium complex (Ir958) was rationally fabricated for S...
Jie Liu, Xuefen Zhao, Huiying Li et al.· RSC Advances· 0 citations
Photodynamic therapy (PDT) can elicit antitumor immunity by inducing immunogenic cell death (ICD), making it an attractive option for postoperative local cancer treatment. However, in solid tumors, aberrant vasculature and an immunosuppressive microenvironment often restrict immune-cell infiltration, thereby weakening...
A multifunctional hydrogel loaded with a novel cyanine nanozyme and Escherichia coli combines efficient photothermal therapy, photodynamic therapy, and peroxidase‐like enzyme activity to provide a novel and effective strategy for postoperative tumor therapy and recurrence inhibition.
Cong Jiang, Zi-Fan Yang, Rong Guo et al.· Advancement of science· 0 citations
The collaboration of two types of CMNPs using a double-layered spherical scaffold efficiently suppressed the development of multiple colorectal cancer models and provides a new solution for the collaboration of CMNPs in tumor immunogene therapy.
Jingmei Li, Jin Zhang, Xia-Yu Chen et al.· Small· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.